Poster presentation on TB-Bs1's therapeutic potential in ROR2 positive cancers at SITC 2024 NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, today announced that it will present a...
Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Seaking AlphaSeeking Alpha / Seaking Alpha 19 hours ago 1 Views
Comments